Arena Pharmaceuticals, Inc. (ARNA)
-NasdaqGS 7.92 
0.07(0.88%) 4:00PM EDT|After Hours
:
7.92 0.00 (0.00%) 7:28PM EDT
| Prev Close: | 7.99 |
|---|
| Open: | 7.98 |
|---|
| Bid: | 7.91 x 10200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 8.36 |
|---|
| Beta: | -0.54 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 7.90 - 8.05 |
|---|
| 52wk Range: | 5.78 - 13.50 |
|---|
| Volume: | 3,681,530 |
|---|
| Avg Vol (3m): | 5,326,290 |
|---|
| Market Cap: | 1.72B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.37 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Arena Pharmaceuticals - Out To Launch Or Out To Lunch?at Seeking Alpha(Wed 3:19AM EDT)
- The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Doesat Seeking Alpha(Tue, May 21)
- The 9 Most Obese Countries in the Worldat Motley Fool(Mon, May 20)
- Arena NOLs Will Come Into Play Soonat Seeking Alpha(Mon, May 20)
- Vivus Taps Into More Cashat Seeking Alpha(Sun, May 19)
- 25 Belt-Busting Obesity Factsat Motley Fool(Sat, May 18)
- ARENA PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Arena Outlines Belviq Launch And Goalsat Seeking Alpha(Fri, May 17)
- Weight Loss Isn't Just for Looking Good Anymoreat Motley Fool(Wed, May 15)
- Vivus - Mild Drama Continuesat Seeking Alpha(Wed, May 15)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, May 15)
- Looking at Arena Following Sell-Offat Motley Fool(Tue, May 14)
- Vivus Starting To Gain The Advantage Over Arenaat Seeking Alpha(Tue, May 14)
- Shorting Arena Is Not a Good Idea Nowat Motley Fool(Tue, May 14)
- Arena, Vivus, And Off-Label Prescriptionsat Seeking Alpha(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 62.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.14 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.12 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | -2.29 |
|---|
Business Summary
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory,...
View More